

National Medicines Regulatory Authority No: 120, Norris Canal Road, Colombo 10, Sri Lanka

Telephone: +94 112 698 896/7

Fax:+94 112 689 704

Web: www.cdda.gov.lk

Check List for Evaluation of Borderline Products

- 1. Application Number:
- 2. Classification Number:
- 3. Date of application submit to the NMRA:
- 4. Date taken for evaluation:
- 5. Authorization letter addressed to CEO / NMRA by the Manufacturer: Yes / No
- 6. Sample Import License: Yes / No
- 7. Whole Sale License: Yes / No

6. Brand Name of the Product:

7. Borderline Product:						V- 1
8. Registration status:		New		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	RR	
9. Route of administration:			Dosage F If applic	orm able only)		
10. Type of product:	- Daniel	Medicine and Medicine and Food Medical Device		Medicine and Cosmetic		
11. Details of the Marketing Name of the applicant	Authorization holder (A	Applicant) ir	ı Sri Lan	ka		
rvaine of the applicant						
Address of the applicant						To the state of th
12.Details of the Manufactur	rer (Please "√" where	needed)				
Manufacturer Name		Water .	The state of the s	7 100		· · · · · · · · · · · · · · · · · · ·
Actual manufacturer	Contract manufactur	er		Other		
Address of the Manufacturing Site		Other add	ress			
13. Is this product registered	Registered		Marketed			
country of manufacture ("\forall"")		Yes		Vo	Yes	No
Classifica	tion of the product in co	ountry of ma	anufactur	e (Please "	√")	2
Borderline Product		200	COSMA.		() () () () () () () () () ()	
Complementary medicine				1 372		

					· · · · · · · · · · · · · · · · · · ·			
Health supplement Listed product	NAME OF THE OWNER, THE	- 52		(*** *********				,
Cosmetic Product	-					S. 198414		
Traditional Medicines								
Medical Device (Type of classificat	tion if an	17/)						
Other (specify)	tion ii ai	iy)						
(cpoint)								
Comments:					7			
	No							100
14. Product Indications /Usage (fund	ctions/ cl	aims)						
	1799 500-5							
								1.00
		,						
								-
•		***		***************************************	- <u>- 40</u>			
If it is a Device								
Does this product require dedicated	If Yes		Details					
instrumentation?								
Availability of User Manual	Yes	No	Manual v	ersion	no /s			-
Comment:				400				
5 Status of the Draduct in	T	•						
15. Status of the Product in		gistere		Mark	ceted	Pro	duct Classi	fication
reference countries	Re Yes			Mark 'es	ceted No	Pro	duct Classi	fication
reference countries i. Australia						Pro	duct Classi	fication
reference countries i. Australia ii. Canada						Pro	duct Classi	fication
i. Australia ii. Canada iii. European Union (EU)						Pro	duct Classi	fication
i. Australia ii. Canada iii. European Union (EU) iv. Japan						Pro	duct Classi	fication
i. Australia ii. Canada iii. European Union (EU) iv. Japan v. New Zealand						Pro	duct Classi	fication
i. Australia ii. Canada iii. European Union (EU) iv. Japan v. New Zealand vi. Singapore						Pro	duct Classi	fication
i. Australia ii. Canada iii. European Union (EU) iv. Japan v. New Zealand vi. Singapore vii. UK						Pro	duct Classi	fication
i. Australia ii. Canada iii. European Union (EU) iv. Japan v. New Zealand vi. Singapore vii. UK viii. USA						Pro	duct Classi	fication
i. Australia ii. Canada iii. European Union (EU) iv. Japan v. New Zealand vi. Singapore vii. UK viii. USA ix. Malaysia						Pro	duct Classi	fication
i. Australia ii. Canada iii. European Union (EU) iv. Japan v. New Zealand vi. Singapore vii. UK viii. USA ix. Malaysia x. Thailand						Pro	duct Classi	fication
i. Australia ii. Canada iii. European Union (EU) iv. Japan v. New Zealand vi. Singapore vii. UK viii. USA ix. Malaysia x. Thailand xi. India						Pro	duct Classi	fication
i. Australia ii. Canada iii. European Union (EU) iv. Japan v. New Zealand vi. Singapore vii. UK viii. USA ix. Malaysia x. Thailand						Pro	duct Classi	fication
i. Australia ii. Canada iii. European Union (EU) iv. Japan v. New Zealand vi. Singapore vii. UK viii. USA ix. Malaysia x. Thailand xi. India						Pro	duct Classi	fication
i. Australia ii. Canada iii. European Union (EU) iv. Japan v. New Zealand vi. Singapore vii. UK viii. USA ix. Malaysia x. Thailand xi. India Any other (specify)	Yes					Pro	duct Classi	fication
i. Australia ii. Canada iii. European Union (EU) iv. Japan v. New Zealand vi. Singapore vii. UK viii. USA ix. Malaysia x. Thailand xi. India Any other (specify)	Yes					Pro	duct Classi	fication
i. Australia ii. Canada iii. European Union (EU) iv. Japan v. New Zealand vi. Singapore vii. UK viii. USA ix. Malaysia x. Thailand xi. India	Yes		No Y			Pro		

16.2 Original Certificate of Free Sale (CFS)					
Valid at the maint. Co. 1					
Valid at the point of submission					
16.3 Certificate of Good Manufacturing Practice (GMP) / ISO ce	ertificate		_	
16.4. Formulation of the Finished Product			1		
Master formula (Approved					
Master formula (Approved master formula is Manufacturing formula with batch size	sued by classif	fication stage)			
Validated testing procedure for finished prod					
Validation report	uct				
Manufacturing process or flow diagram					
Comment:					
16.5. Quality Control					
DI					
Please "√"	Certificate of Analysis Stability Ren				
	Certificate of Analysis Stability (COA)				
Annegrance	Yes	No	Yes	N.	
Appearance			103	No	
Chemical Assay for active ingredients Limits for heavy metals					
Limits for microbial contamination					
Disintegration test					
Any other specific test					
Comment:					
Complete original real time stability data al. 111					
Complete original real time stability data should be ears of the product registration. Failure on submission of the documents are submitted; the registration of	submitted at le	ast for two com	mercial bate	hes after	
omplete documents are submitted: the registers!	Cut will cause ii	re product to be	suspended u	intil the	
ocuments still cannot be produced upon renewal of p	the product w	ill be terminate	d if the com	olete	
produced upon renewal of p	product registra	ation.			
7. Efficacy data if available					
1.11.1	Ye	es			
iblished reports		03	No)	
etan Clinical trial report for the product if available	the second second				
etail Clinical trial report for the product if available omment:					
omment:					
omment:					

18.Composition per dosage form (Tablet/ Capsule/Gel, etc) Write the dosage and the strength (if required)

Botanical name (if available)		Hunction
	Amount	Function
	-	

19. Instrument with standard accessories and Name of the accessory / spare part	Catalogue number	Function
		1 diletion

Leaflet, Pro ((Please "	formation Leaflet (PIL), Consumer Information romotional materials, Label & Packaging materials				Yes		No	
Original PIL	Product nam	e						
	Ingredient li				·			
22.20	Indication							
	Contra indic	ations						
	Warnings / F	recautions				_	-	
	Dose		-		-			
	Side effects							
	Storage cond	itions		_	-	-		
		ne manufacturer				-		
	Any other			_		+		
Original Packaging			Primary Pack		Secondary Pack			
<u> </u>				Yes	No	Yes	No	
Original	Ingredient Li	st	7007			1 200	110	
Labeling	Storage						USBS HIS	
	Heath Claims			2000			-	
	Manufacture	Name & Address						
	Manufacturin	g Date					-	
	Expiry Date							
<u> </u>	Batch No							
Original Promot	ional materials							
Are there any vis	sual graphics or	the product / PIL						
If Yes, describe								
Schedule		I	IIA	- T		IIB		
Recommendation Pharmacist	n of the				5.390			
Date		Signature						

Expert Comment

1. Application Number:

Name of the appli		
	ssion of the application to the expert:	
4. Date taken for eva	aluation:	
5. Expert's Commer	t:	
	v	
	v	
		in the second se
	1	
		-
6. Any other comm	ent:	
	A STATE OF THE STA	
Recommendation:	Name:	
	Building Company	
	Designation:	
	Signature:	
		Approved by CEO